



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Mark Hackett**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi.
We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-I-054**

You asked:

I am interested to know the total number of patients with breast cancer treated with medicines between Apr 2022 and Aug 2022. When responding to the questions below please count all patients treated with chemotherapies, biological agents, hormonal therapies etc., but exclude patients treated with surgery only and/or radiotherapy only.

1. How many patients with breast cancer were treated in total?

Please note that we are only able to provide the number of patients treated with SACT (systemic anti-cancer therapy). Hormone treatments are not prescribed on our centralised system. I can confirm that none of the below information is recorded centrally on our systems. In order to obtain this information would involve a manual trawl of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

219 patients

2. How many patients with breast cancer were treated at the following stages?

Please note that patients on our systems are only categorised as early or advanced breast cancer, therefore this is the information we have provided. Further, please note that some early breast cancer patients will have progressed on



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

treatment and so will be counted in both early and advanced figures.

- **Early breast cancer**
- **Advanced breast cancer**

| |
|-----|
| 98 |
| 126 |

3. How many patients with breast cancer were treated in the following categories of tumour characteristics and staging?

I can confirm that none of the below information is recorded centrally on our systems. In order to obtain this information would involve a manual trawl and cross referencing of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

| | | | |
|-----------------------|-------------|------------------------------------|--|
| • Early breast cancer | Neoadjuvant | HR+ve (ER+ve &/or PR+ve) | |
| • Early breast cancer | Adjuvant | HR+ve (ER+ve &/or PR+ve) | |
| • Early breast cancer | Neoadjuvant | HR+ve, HER2+ve | |
| • Early breast cancer | Adjuvant | HR+ve, HER2+ve | |
| • Early breast cancer | Neoadjuvant | HR+ve, HER2-ve | |
| • Early breast cancer | Adjuvant | HR+ve, HER2-ve | |
| • Early breast cancer | Neoadjuvant | HR+ve, HER2-ve, node positive | |
| • Early breast cancer | Adjuvant | HR+ve, HER2-ve, node positive | |
| • Early breast cancer | Neoadjuvant | HER2+ve, node positive | |
| • Early breast cancer | Adjuvant | HER2+ve, node positive | |
| • Early breast cancer | Neoadjuvant | BRCA1/2 germline mutation positive | |
| • Early breast cancer | Adjuvant | BRCA1/2 germline mutation positive | |
| • Early breast cancer | Neoadjuvant | Triple negative | |
| • Early breast cancer | Adjuvant | Triple negative | |
| • Early breast cancer | All | PIK3CA mutation | |
| • Locally advanced | All | HR+ve (ER+ve &/or PR+ve) | |



| | | | |
|--------------------|-----|---------------------------------------|--|
| • Locally advanced | All | HER2+ve | |
| • Locally advanced | All | HR+ve, HER2-ve | |
| • Locally advanced | All | BRCA1/2 germline mutation positive | |
| • Locally advanced | All | Triple negative, PD-L1 positive | |
| • Locally advanced | All | Triple negative, PD-L1 negative | |
| • Locally advanced | All | PIK3CA mutation | |
| • Metastatic | All | HR+ve (<i>ER+ve &/or PR+ve</i>) | |
| • Metastatic | All | HER2+ve | |
| • Metastatic | All | HR+ve, HER2-ve | |
| • Metastatic | All | BRCA1/2 germline mutation positive | |
| • Metastatic | All | Triple negative, PD-L1 positive | |
| • Metastatic | All | Triple negative, PD-L1 negative | |
| • Metastatic | All | PIK3CA mutation | |

